eef-1G Antibody

What is EEF-1G and what is its function in cellular processes?

EEF-1G (elongation factor-1 gamma), also known as EF-1 gamma or GIG35, is a 437 amino acid subunit of the eukaryotic elongation factor-1 (EF-1) complex. This multi-protein complex plays a central role in protein synthesis by facilitating the delivery of aminoacyl-tRNAs to the ribosome during translation elongation . EEF-1G contains an N-terminal Glutathione transferase domain which is thought to be involved in anchoring the complex to various cellular components, thus providing structural support for the translation machinery .

Additionally, EEF-1G may play a key role in the assembly of multiprotein complexes containing aminoacyl-tRNA synthetases, further supporting its importance in protein synthesis regulation . The protein is widely expressed across multiple tissues including stomach, pancreas, brain, lung, kidney, intestine, liver, and spleen, indicating its fundamental role in cellular physiology . Recent research has also implicated EEF-1G in processes beyond translation, including potential roles in oncogenic transformation, as increased expression levels have been associated with pancreatic cancer .

What are the standard applications for EEF-1G antibodies in molecular biology research?

EEF-1G antibodies are versatile tools in molecular biology research with several standard applications:

• Western Blotting (WB): EEF-1G antibodies can be used at dilutions ranging from 1:500 to 1:2000 for detecting the protein in cell and tissue lysates . This technique is particularly useful for quantifying expression levels across different experimental conditions or comparing expression across various cell lines.

• Immunohistochemistry (IHC): At dilutions of 1:50 to 1:100, these antibodies can visualize EEF-1G distribution in paraffin-embedded tissue sections . IHC applications have successfully demonstrated EEF-1G expression in human esophagus and rat brain tissues .

• Immunofluorescence (IF): Similar to IHC, IF applications typically use dilutions of 1:50 to 1:100 to examine subcellular localization of EEF-1G . Studies have shown that EEF-1G is predominantly distributed in the cytoplasm of cells, consistent with its role in translation .

• Protein-Protein Interaction Studies: EEF-1G antibodies can be employed in co-immunoprecipitation assays to investigate interactions with other components of the translation machinery or novel binding partners.

These applications provide researchers with comprehensive tools to study EEF-1G expression, localization, and function in various experimental contexts.

How should researchers validate the specificity of EEF-1G antibodies?

Validating antibody specificity is crucial for obtaining reliable research results. For EEF-1G antibodies, researchers should implement the following validation strategies:

• Positive and Negative Controls: Include cell lines or tissues known to express high levels of EEF-1G as positive controls, and consider using cell lines with CRISPR/Cas9-mediated EEF-1G knockdown as negative controls, similar to the approach used in studies of EEF-1G function in viral replication .

• Western Blot Analysis: Confirm the detection of a band at the expected molecular weight (~50 kDa for human EEF-1G). Multiple cell lines should be tested to ensure consistent results across different cellular contexts .

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide before application to samples; this should abolish specific signals if the antibody is truly specific.

• Orthogonal Validation: Compare results using antibodies targeting different epitopes of EEF-1G or using alternative detection methods such as mass spectrometry.

• Genetic Models: When possible, use genetic models with altered EEF-1G expression. For example, the study on influenza virus replication utilized cells with defective EEF-1G expression generated through CRISPR/Cas9, which provided a controlled system to validate antibody specificity .

Implementing these validation steps ensures that experimental observations are genuinely attributable to EEF-1G rather than non-specific antibody binding.

How can EEF-1G antibodies be used to investigate its role in viral replication?

EEF-1G has been identified as a host factor that contributes to influenza A virus replication in a strain-specific manner. Researchers can employ EEF-1G antibodies to elucidate its role in viral pathogenesis through several methodological approaches:

• Protein-Virus Interaction Studies: Co-immunoprecipitation experiments using EEF-1G antibodies can identify interactions with viral proteins. Previous interactome analysis revealed that EEF-1G interacts with several influenza virus proteins including PB2, PB1, PA, and NP .

• Localization During Infection: Immunofluorescence assays using EEF-1G antibodies can track changes in its subcellular distribution during viral infection, potentially revealing recruitment to viral replication complexes .

• Expression Analysis in Modified Cell Lines: Western blot analysis with EEF-1G antibodies can monitor expression levels in cells with genetically modified EEF-1G (such as those created using CRISPR/Cas9) to correlate expression with viral replication efficiency .

• Strain-Specific Effects: When investigating viruses like influenza A, researchers should use EEF-1G antibodies to compare protein expression and localization during infection with different viral strains. This approach helped demonstrate that while A/WSN/33 (H1N1) virus growth was significantly suppressed in cells with defective EEF-1G expression, A/California/04/2009 (H1N1pdm) virus replication remained largely unaffected .

• Complementation Studies: In cells with defective EEF-1G expression, researchers can use antibodies to confirm the restoration of EEF-1G levels following transfection with gRNA-resistant EEF-1G constructs, thereby validating rescue experiments .

These methodologies enable detailed investigation of the mechanisms by which EEF-1G facilitates viral protein synthesis in a strain-dependent manner.

What methodological considerations are important when using EEF-1G antibodies in multiplex immunostaining?

When incorporating EEF-1G antibodies into multiplex immunostaining protocols, researchers should address several methodological considerations:

• Antibody Compatibility: Ensure that primary antibodies are derived from different host species (e.g., rabbit anti-EEF-1G with mouse antibodies against other targets) to avoid cross-reactivity with secondary detection reagents.

• Epitope Retrieval Optimization: Different antigens may require specific antigen retrieval methods. Optimize conditions that preserve EEF-1G epitopes while maintaining detection of other target proteins.

• Sequential vs. Simultaneous Staining: Evaluate whether sequential or simultaneous application of antibodies provides better results. For EEF-1G, which is predominantly cytoplasmic, sequential staining may reduce background when combining with nuclear markers.

• Signal Amplification Considerations: When detecting low-abundance proteins alongside EEF-1G, consider using amplification systems selectively for the less abundant targets while using standard detection for EEF-1G.

• Spectral Overlap Management: Select fluorophores with minimal spectral overlap for multiplexed detection, particularly when visualizing EEF-1G alongside other cytoplasmic proteins.

• Validation Controls: Include single-stain controls, no-primary controls, and isotype controls to assess antibody specificity and potential cross-reactivity in the multiplex system.

Implementing these considerations ensures reliable detection of EEF-1G in conjunction with other proteins of interest, facilitating complex analyses of protein co-expression and co-localization.

How does EEF-1G expression correlate with cancer progression, and how can antibodies facilitate this research?

Increased expression of EEF-1G has been associated with pancreatic cancer, suggesting a potential role in oncogenic transformation . Researchers can leverage EEF-1G antibodies to investigate this correlation through several approaches:

• Tissue Microarray Analysis: EEF-1G antibodies can be applied to tissue microarrays containing samples across different cancer stages to quantify expression changes during disease progression.

• Patient-Derived Xenograft Models: Immunohistochemical staining with EEF-1G antibodies can assess expression in patient-derived xenografts to correlate protein levels with tumor aggressiveness and treatment response.

• Prognostic Marker Evaluation: By analyzing EEF-1G expression using antibodies in retrospective patient cohorts with known outcomes, researchers can assess its potential as a prognostic biomarker.

• Functional Studies Using Antibody-Based Techniques: Researchers can employ techniques like Proximity Ligation Assay (PLA) with EEF-1G antibodies to investigate protein-protein interactions that may be altered in cancer cells.

• Quantitative Analysis Methods: Implementing digital pathology approaches with EEF-1G immunostaining allows precise quantification of expression levels across multiple tumor samples, enabling correlation with clinical parameters.

These methodological approaches provide researchers with tools to systematically investigate the relationship between EEF-1G expression and cancer development, potentially revealing new therapeutic targets or diagnostic markers.

What are the optimal conditions for using EEF-1G antibodies in Western blotting?

To achieve optimal results when using EEF-1G antibodies in Western blotting, researchers should consider the following technical parameters:

• Sample Preparation: For cell lysates, use RIPA buffer with protease inhibitors. Load approximately 25μg of protein per lane for adequate detection of EEF-1G .

• Blocking Conditions: Use 3% non-fat dry milk in TBST as blocking buffer to minimize background while maintaining specific signal .

• Primary Antibody Dilution: For most applications, a 1:1000 dilution of EEF-1G antibody is recommended, though this may be adjusted to 1:500-1:2000 depending on the specific antibody and sample type .

• Incubation Conditions: Optimal results are typically achieved with overnight incubation at 4°C, though some antibodies may perform well with shorter incubations (2-4 hours) at room temperature.

• Secondary Antibody Selection: Use HRP-conjugated anti-rabbit IgG (for rabbit polyclonal EEF-1G antibodies) at a 1:10,000 dilution .

• Detection System: ECL-based detection systems provide good sensitivity for visualizing EEF-1G. Exposure times around 5 seconds are typically sufficient, though this may vary based on expression levels .

• Expected Results: EEF-1G should appear as a band of approximately 50 kDa. In some experimental conditions, such as cells with genetic modifications affecting EEF-1G, altered banding patterns may be observed (e.g., shorter forms around 37 kDa) .

Following these guidelines will help ensure consistent and specific detection of EEF-1G in Western blotting applications.

How can researchers troubleshoot common issues with EEF-1G antibody applications?

When working with EEF-1G antibodies, researchers may encounter various technical challenges. Here are methodological solutions to common problems:

• Weak or Absent Signal in Western Blotting:

  • Increase protein loading (30-50μg per lane)

  • Decrease antibody dilution (try 1:500)

  • Extend primary antibody incubation time to overnight at 4°C

  • Use more sensitive detection reagents or longer exposure times

  • Verify sample preparation to ensure protein integrity

• High Background in Immunohistochemistry:

  • Optimize blocking (try 5-10% normal serum from the same species as the secondary antibody)

  • Increase washing steps (5 x 5 minutes with gentle agitation)

  • Decrease primary antibody concentration (try 1:200 dilution)

  • Include 0.1-0.3% Triton X-100 in the antibody diluent to reduce non-specific binding

  • Consider using a biotin-streptavidin amplification system for specific signal enhancement

• Non-specific Bands in Western Blotting:

  • Increase blocking time and concentration

  • Add 0.1% SDS to antibody dilution buffer

  • Use gradient gels to better resolve proteins of similar molecular weights

  • Perform peptide competition assays to confirm specificity

• Poor Reproducibility Between Experiments:

  • Standardize protein extraction and quantification methods

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Use the same lot number of antibody when possible

  • Implement positive and negative controls in each experiment

• Discrepancies in Localization Studies:

  • Compare fixation methods (paraformaldehyde vs. methanol)

  • Validate with multiple antibodies targeting different epitopes

  • Complement with subcellular fractionation and Western blotting

These troubleshooting approaches address the most common technical challenges researchers face when working with EEF-1G antibodies across different applications.

How can EEF-1G antibodies be used to study its role in protein complex assembly?

EEF-1G may play a key role in the assembly of multiprotein complexes containing aminoacyl-tRNA synthetases . Researchers can employ EEF-1G antibodies to investigate this role through several methodological approaches:

• Co-Immunoprecipitation Combined with Mass Spectrometry: Using EEF-1G antibodies for immunoprecipitation followed by mass spectrometric analysis can identify novel interaction partners within these complexes. This approach is similar to the tissue-immunoprecipitation (TIP) combined with mass spectrometric analysis used in autoantibody studies .

• Proximity-Dependent Biotinylation (BioID or TurboID): By fusing EEF-1G to a biotin ligase and using antibodies to validate the expression of the fusion protein, researchers can identify proteins in close proximity to EEF-1G in living cells.

• Size Exclusion Chromatography Coupled with Western Blotting: Fractionating cell lysates by size and probing fractions with EEF-1G antibodies can reveal the distribution of EEF-1G across different protein complexes.

• Native Gel Electrophoresis: Using EEF-1G antibodies to probe native gels can preserve protein-protein interactions and reveal which complexes contain EEF-1G.

• Fluorescence Resonance Energy Transfer (FRET): Combining fluorescently labeled EEF-1G antibodies with antibodies against potential interaction partners can detect protein proximity in fixed cells.

• Effect of EEF-1G Depletion on Complex Formation: Using Western blotting with antibodies against eEF1B2 and eEF1D in cells with reduced EEF-1G expression can reveal how EEF-1G affects the stability of other complex components, as demonstrated in previous research where eEF1B2 and eEF1D levels were reduced in cells with defective EEF-1G expression .

These methodologies provide complementary approaches to dissect the role of EEF-1G in organizing and stabilizing multiprotein complexes involved in translation.

What considerations are important when using EEF-1G antibodies in studies of post-translational modifications?

Investigating post-translational modifications (PTMs) of EEF-1G requires specific methodological considerations when using antibodies:

• Selection of PTM-Specific Antibodies: When available, use antibodies that specifically recognize phosphorylated, ubiquitinated, or otherwise modified forms of EEF-1G. These should be validated using appropriate positive controls.

• Preservation of PTMs During Sample Preparation: Include phosphatase inhibitors (e.g., sodium orthovanadate, β-glycerophosphate) when studying phosphorylation, or deubiquitinase inhibitors (e.g., N-ethylmaleimide) when studying ubiquitination.

• Two-Dimensional Gel Electrophoresis: Combine with Western blotting using EEF-1G antibodies to separate protein isoforms with different PTMs based on both molecular weight and isoelectric point.

• Phos-tag™ SDS-PAGE: This specialized electrophoresis technique, combined with standard EEF-1G antibodies, can separate phosphorylated from non-phosphorylated forms without requiring phospho-specific antibodies.

• Immunoprecipitation-Mass Spectrometry Workflow: Use EEF-1G antibodies to immunoprecipitate the protein, followed by mass spectrometry to identify specific modification sites and types.

• Treatment with Modifying/Demodifying Enzymes: Compare EEF-1G immunoblot profiles before and after treatment with phosphatases, deubiquitinases, or other enzymes that remove specific PTMs.

• Correlation with Cellular Conditions: Analyze changes in EEF-1G PTM patterns using appropriate antibodies under different cellular stresses, during cell cycle progression, or in response to signaling pathway activation.

These approaches enable comprehensive characterization of EEF-1G post-translational modifications and their functional significance in different physiological and pathological contexts.

What are emerging applications of EEF-1G antibodies in clinical research?

While EEF-1G antibodies are primarily used in basic research, several emerging applications in clinical research show promise:

• Biomarker Development: The association between EEF-1G expression and pancreatic cancer suggests potential utility as a diagnostic or prognostic biomarker . Immunohistochemical analysis using validated EEF-1G antibodies could be standardized for clinical sample evaluation.

• Autoimmune Disease Research: Similar to the discovery of autoantibodies against EEF1D in autoimmune cerebellar ataxia , EEF-1G antibodies can be used to investigate whether EEF-1G serves as an autoantigen in certain neurological or autoimmune conditions.

• Infectious Disease Mechanisms: The strain-specific role of EEF-1G in influenza virus replication suggests potential applications in studying host-pathogen interactions in clinical isolates, which could inform therapeutic strategies targeting host factors.

• Personalized Medicine Approaches: EEF-1G antibodies could help stratify patients based on protein expression patterns, potentially predicting response to certain treatments, particularly in cancer therapy.

• Liquid Biopsy Development: Exploring whether EEF-1G or its modified forms are detectable in circulation could lead to minimally invasive diagnostic approaches for conditions associated with altered EEF-1G expression.

These emerging applications represent promising directions for translating basic research on EEF-1G into clinical settings, though further validation studies are needed before clinical implementation.